Work

A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.tps3637

Authors: Scott Kopetz, Van K. Morris, Bert O'Neil, John A. Bridgewater, Janet Graham, Eileen E. Parkes, Mark P. Saunders, Elspeth Asken, Louise Goodwin, Caroline Phillips, Jane Robertson, Craig Tilston, Simon Woodcock, Natalie Cook

Institutions: The University of Texas MD Anderson Cancer Center, University College London, Beatson West of Scotland Cancer Centre, Churchill Hospital, Oxford University Hospitals NHS Trust, The Christie NHS Foundation Trust, Redx Pharma (United Kingdom), The Christie Hospital

Language: English

Topic: Wnt/β-catenin signaling in development and cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4281858602

Cites:

Cited by: 9

Related to: 10